Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach  by Zervou, Maria et al.
Biochimica et Biophysica Acta 1838 (2014) 1031–1046
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemInsights into the molecular basis of action of the AT1 antagonist losartan
using a combined NMR spectroscopy and computational approachMaria Zervou a,⁎, Zoe Cournia b, Constantinos Potamitis a, George Patargias b, Serdar Durdagi a,1,
Simona Golic Grdadolnik c,d, Thomas Mavromoustakos a,e
a National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry & Biotechnology, Vas. Constantinou 48, 11635 Athens, Greece
b Biomedical Research Foundation of the Academy of Athens, 4, Soranou Efesiou, 11527 Athens, Greece
c Laboratory of Biomolecular Structure, National Institute of Chemistry, Hajdrihova 19, POB 30, SI-1115 Ljubljana, Slovenia
d EN-FIST Centre of Excellence, Dunajska 156, SI-1000 Ljubljana, Slovenia
e Chemistry Department of National Capodistrian University, Zographou, Athens 15784, Greece⁎ Corresponding author.
E-mail address:mzervou@eie.gr (M. Zervou).
1 Current address: Bahcesehir University, Faculty of Med
34353 Istanbul, Turkey.
0005-2736/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbamem.2013.12.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 August 2013
Received in revised form 17 December 2013
Accepted 19 December 2013
Available online 27 December 2013
Keywords:
Losartan
SDS micelles
NMR (DOSY, NOESY/ROESY)
Spin labels
Molecular dynamics in micelles
Molecular dynamics in phospholipid bilayers
with embedded AT1 receptorThe drug:membrane interactions for the antihypertensive AT1 antagonist losartan, the prototype of the sartans
class, are studied herein using an integrated approach. The pharmacophore arrangement of the drug was
revealed by rotating frame nuclear Overhauser effect spectroscopy (2D ROESY) NMR spectroscopy in three
different environments, namely water, dimethyl sulfoxide (DMSO), and sodium dodecyl sulfate (SDS) micellar
solutions mimicking conditions of biological transport ﬂuids and membrane lipid bilayers. Drug association
with micelles was monitored by diffusion ordered spectroscopy (2D DOSY) and drug:micelle intermolecular
interactionswere characterized by ROESY spectroscopy. The localisation of the drug in themicellar environment
was investigated by introducing 5-doxyl and 16-doxyl stearic acids. The use of spin labels conﬁrmed that losartan
resides close to themicelle:water interfacewith thehydroxymethyl group and the tetrazole heterocyclic aromatic
ring facing the polar surface with the potential to interact with SDS charged polar head groups in order to
increase amphiphilic interactions. The spontaneous insertion, the diffusion pathway and the conformational
features of losartanweremonitored byMolecular Dynamics (MD) simulations in amodeled SDSmicellar aggregate
environment and a long exploratory MD run (580 ns) in a phospholipid dipalmitoylphosphatidylcholine (DPPC)
bilayer with the AT1 receptor embedded. MD simulations were in excellent agreement with experimental results
and further revealed the molecular basis of losartan:membrane interactions in atomic-level detail. This applied
integrated approach aims to explore the role of membranes in losartan's pathway towards the AT1 receptor.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
In the absence of crystallographic or spectroscopic data associated
with a speciﬁc target receptor such as in the case of the AT1 receptor,
which belongs to the class A G-protein-coupled receptors (GPCRs), a
ligand-based pharmacophore approach or a model receptor using a
solved structure as template from the same receptor class can be
applied in virtual screening, de novo drug design, and lead optimization
[1,2]. In thedrug design process, one important aspect is the relationship
between conformation and bioactivity [3,4]. Flexible pharmacophore
segments of the ligand allow the drug to adopt different low-energy con-
formations comprising the bioactive conformation(s) upon binding in
the active site of the target. Treating ligand conformational ﬂexibility,
is a challenging task for the process of alignment and the construction
of pharmacophore models [1]. Tracing an ensemble of low energyicine, Department of Biophysics,
ights reserved.drug conformers using NMR experimental restraints and conformation-
al analysis methods could signiﬁcantly assist the procedure.
Sartans are pharmaceuticals, whichmodulate the renin–angiotensin–
aldosterone system. They antagonize with high selectivity the binding of
the vasoconstrictor hormone Angiotensin II (ANG II) at the AT1 receptor.
Losartan potassium is a paradigm of successful rational drug design since
its molecular structure is based on the mimicry of the C-terminal part of
ANG II [5]. Losartan is well-absorbed orally and its hydroxymethyl
group is rapidly converted via oxidation to carboxylate moiety in the
human liver resulting to the potent metabolite EXP-3174, which extends
the antihypertensive effects of the drug [6].
1.1. Conformational ﬂexibility of losartan
In a previous study [7], we applied conformational analysis of
losartan potassium in dimethyl sulfoxide (DMSO) using a combination
of NMR spectroscopy and molecular modeling techniques. The ﬂexible
pharmacophore segments of losartan (Scheme 1) allow it to adopt
many low energy conformers. In particular, the tetrazole and imidazole
moieties may adopt an anti or syn orientation with respect to the A
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is also mirrored in the positioning of the butyl chain either towards the
tetrazole, possibly driven by C-H/π interactions, or away from it, pointing
towards the opposite side of the space occupied by tetrazolewith respect
to the A phenyl ring plane (Fig. 1). Superimposition studies with the C-
terminal segment of sarmesin, a competitive peptide antagonist of ANG
II, showed an excellent ﬁt with the anti conﬁguration of the tetrazole
and imidazole rings. [7]. The anti orientation was also determined
in the crystals of losartan's anionic form grown in ethanol/water solu-
tion [8] or in aqueous solution [9], while the syn orientation was preva-
lent for the neutral form obtained in dioxan solution [10].
1.2. Interaction of losartan with membrane bilayers
Our previous studies employing Differential Scanning Calometry
(DSC), 13C Magic Angle Spinning (13C MAS), and 31P Cross-Polarization
(31P CP) solid state NMR spectroscopy in dipalmitoylphosphatidylcholine
(DPPC) bilayers loaded with losartan have conﬁrmed the interaction of
losartan with this model lipid membrane. We observed that the drug
interacts mainly with the interface region of the bilayer and anchors inScheme 1.Molecular structures of losartan, SDS, and of the spin-labeled 5- and 16-doxyl stearic
are also deﬁned.the realm of the headgroup region. Moreover, molecular modeling
studies of losartan in DPPC bilayers indicated the localization of the drug
at the interface region favoring electrostatic interactions between the hy-
droxyl and tetrazole groups of the drug with the polar headgroups and
diffusing water molecules [11–13]. The interaction of losartanwith phos-
pholipid membranes was further conﬁrmed by Electron Spin Resonance
(ESR) studies leading to the speculation that losartan may exert some of
its effects through interactionwith the lipids of themembrane bilayer be-
sides its direct antagonistic action on the receptor [14]. This data is consis-
tent with our proposed diffusionmodel according to which the favorable
insertion of the drug into the interface is required for its diffusion towards
the transmembrane (TM) active site of the AT1 receptor [11].
1.3. Modeling of GPCRs and membrane diffusion hypothesis
The lack of crystallographic data for the human AT1 (hAT1) receptor
and the notable ﬂexibility of losartan has led to a discrepancy regarding
the speciﬁc binding site and bioactive modes of the drug. The ligand
binding site has been determined based on homology modeling of the
hAT1 or the rat AT1 receptors using structural models of rhodopsinacids. The critical dihedral angles of losartan that determine its conformational properties
Fig. 1. Superimposition of one anti (crystal structure from [8] in cyan) and two syn (crystal
structure from [9] in yellow and one theoretically derived low-energy conformer in blue)
conformations of losartan, placing tetrazole and imidazole moieties in an anti or a syn ori-
entation with respect to the A phenyl ring plane. The different butyl chain orientations ei-
ther towards the tetrazole or away from it, pointing towards the opposite side of theA ring
plane, are also depicted for the two syn conformers (yellow and blue respectively).
1033M. Zervou et al. / Biochimica et Biophysica Acta 1838 (2014) 1031–1046photointermediates and site-directedmutagenesis studies. The predicted
binding site for sartans is located at the upper part of the receptor
between the transmembrane helices 3–7 (TM3-7) and the extracellular
loop 2 (ECL2) [15–17]. Moreover, mutational studies have revealed
that ligand-speciﬁc conformational changes induced to the ECL2 are
responsible for the switch between the active and inactive state of the
receptor [18].
Recently, resolved crystal structures of the ligand activated turkey
β1- and human β2-adrenergic, the human A2A-adenosine, the human
dopamine D3 and the human chemokine CXCR4 GPCR class A receptors
with antagonists bound, have identiﬁed structural differences with
respect to the rhodopsin receptor. Open clefts in the extracellular
regions may guide the entrance of the sartans towards the active site,
whereas in rhodopsin the ECL-2 sits above the binding site and encloses
it [19,20]. In line with this, the most recently developed homology
model of AT1 based on the chemokine CXCR4 receptor, which was
published after this study was performed, highlights the higher accessi-
bility of the binding site to the extracellular environment [21,22].
Since sartans' pathway to approach the active site of AT1 receptor
has not been elucidated, both direct and membrane-mediated routes
could underlie the drug action. Thus, the hypothesis of the lateral
diffusion of the antagonist through the membrane in order to access
the binding site merits further investigation.1.4. Probing drug–membrane interactions
In this context, the molecular mechanism of drug:membrane interac-
tions poses another issue of high signiﬁcance for the design and screening
of novel drugs. Partitioning of the ligand in the membrane driven by
hydrophobic and electrostatic interactions is the primary mechanism
of drug sequestration with a major impact in drug disposition [23].
Non-speciﬁc binding to the membrane or membrane-embedded recep-
tors could hinder drug access to the binding site; however, diffusion
through the membrane pathway could speed up the process of encoun-
tering the transmembrane binding site as compared to the random hit
of the free ligand at the extracellular part of the receptor [24,25]. A
complex interplay of all these factors will ultimately determine the
overall drug efﬁcacy. Lastly, membrane incorporation of drug molecules
could possibly aid the ligand to adopt a bioactive conformation in order
to interact effectively with a membrane embedded receptor target [24].Phospholipids in the zwitterionic form comprise themost abundant
class of lipid molecules found in cell membranes. The transbilayer
distribution of the lipids across biological membranes is maintained to
be asymmetric, which is a feature mediated by transporter proteins.
Amine-containing phospholipids are found predominantly on the
cytoplasmic surface of the plasma membrane while the concentration
of choline-containing phospholipids and sphingolipids is higher
on the extracellular membrane leaﬂet [28]. Furthermore, saturated
phosphatildylcholine content is predominant ranging around 60% in
vascular smooth muscle cell membranes, where the AT1 receptor is
localized among other tissues and organs [29]. Since the topography of
the losartan binding site is localized in the outer monolayer as reported
in the literature for modeled AT1 receptors [15–17,22,30], DPPCwas the
lipid of choice for the AT1/losartan/lipid bilayer Molecular Dynamics
(MD) simulations implemented in this study.
In order to resolve drug:membrane interactions in atomic resolution,
NMR spectroscopy techniques have been employed in various
membrane-like environments including bicelles, vesicles, or micelles,
which constitute the idealmembranemimetic environment for providing
well resolved NMR spectra, since the tumbling of the membrane-
mimicking aggregates in solution is fast enough [26]. Detergentmicelles
as the anionic sodium dodecyl sulfate (SDS) and the zwitterionic
dodecylphosphocholine (DPC) have been commonly used to resolve
the 3D structure of membrane-interacting peptides and membrane
proteins. However, certain drawbacks have been reported in the litera-
ture such as possible structural distortions induced by the spontaneous
micelle curvature and the loss of functional folding due to detergent
binding in the active site of the protein [27].
Our previous comparative biophysical studies of the sartan class
drugs losartan and candesartan in membrane bilayers, have revealed a
deeper insertion of losartan in DPPC bilayers, which has been attributed
to its higher hydrophobic component, its weaker electrostatic interac-
tionswith themembrane surface (losartan features onenegative charge
due to its acidic tetrazole group as compared to the binary charge of
candesartan due to both the acidic tetrazole and a carboxylate group),
and its higher structural ﬂexibility resulting in amore effective anchoring
at the polar head groups and accommodation between the acyl chains
[31].
The anionic detergent SDS,which encompasses structural character-
istics that mimic the polar phosphate group and the long unbranched
alkyl chains of the DPPC dipalmitoyl segment, was used in this study
as a biomembrane-mimicking environment for the HR NMR studies.
The use of anionic SDS micelles as a membrane mimetic aims to assess
whether the hydrophobic contribution could compensate for the
repulsive electrostatic interactions between the losartan tetrazole
group and themicellar anionic head, enabling the association of losartan
with micelles and spontaneous insertion in the hydrophobic core.
The interaction of valsartan, another member of the sartans, which
bears two weakly acidic functionalities, with SDS micelles has been
demonstrated previously; the study of losartan:SDSmicelle interactions
would enable us to directly compare the two antagonists interacting
with membrane-mimicking systems [32,33].
In the current study, we performed a thorough conformational
analysis of losartan by applying rotating frame nuclear Overhauser
effect (2D ROESY) and nuclear Overhauser effect (2D NOESY) NMR
spectroscopies in three different environments, mimicking conditions
of biological transport ﬂuids and membrane lipid bilayers. In particular,
we have used water, the lower dielectric constant amphiphilic DMSO
solvent mimicking the membrane headgroup/water interface, and
ultimately SDS micellar solution, which additionally probes the hydro-
phobic interior of the bilayers. The calculated proton–proton distances
were then applied as restraints to stochastic dynamics simulations
using implicit solvationmodels in order to extract dynamic information
about the pharmacophore arrangement of the molecule in the three
studied environments. Drug association with micelles was followed
with diffusion ordered spectroscopy (2D DOSY) spectroscopy and
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ROESY spectroscopy. Moreover, the topographical sites of the drug in
the micellar environment were studied by introducing paramagnetic
spin relaxation agents (i.e. 5-doxyl and 16-doxyl stearic acids) to the
micelle solution and observing their effect on the drug resonances.
The unprompted insertion, the diffusion pathway and dynamics of
losartan were monitored by Molecular Dynamics (MD) simulations in
a modeled micellar aggregate environment [34] and a long exploratory
MD run (580 ns) in aDPPC bilayer [35]with theAT1 receptor embedded
[16,36]. This integrated approach aims to investigate the impact of
membranes in losartan's pathway towards the AT1 receptor.
2. Experimental section
Losartan potassium was kindly donated by Merck. Deuterated and
protonated sodium dodecyl sulfate SDS-d25 and SDS-H25 respectively,
and the spin labels 5- and 16-doxylstearatewere purchased from SIGMA.
2.1. NMR samples preparation
Losartanwas studied in DMSO-d6, D2O, andmicellar solutions in two
different concentrations, 5 and 15 mM. The pD values in the aqueous
solutions were 7.8 (5 mM) and 8.2 (15 mM).
The partitioning of the drug in the micellar systems was studied by
adding 5 mM losartan in 400 mM SDS-d25/D2O solution (drug:micelle
preparation A). The preparation was subjected to sonication to provide
a transparent solution. SDS concentration exceeded the critical micelle
concentration (CMC = 8.2 mM) in order to ensure micelle formation
and the applied molar ratio (drug:micelle = 1:80) was used to
establish the immersion of at least one drug molecule in the micellar
aggregate assuming an SDS aggregation number of at least 60monomers
[37]. The pD value in themicellar environment was 8.8. To determine the
location of losartan in the micelle, 5-DSA and 16-DSA water solutions of
50 μL were prepared in a molar ratio of 1:4 (spin label:drug) according
to Ref. [38]. Successive aliquots of 5 μL of each DSA were added in
separate drug:micelle solutions.
In order to elucidate drug:micelle intermolecular interactions, D2O
solutions of 15 mM losartan in 200 mM SDS-H25 or 200 mM SDS-d25
were also prepared (drug:micelle preparations B). The pD values of
the solutions were 9.3 (15 mM drug:200 mM SDS-H25) and 9.8
(15 mM drug:200 mM SDS-d25).
At the given experimental conditions, SDS (pKa = 1.9) and the
acidic tetrazole of losartan (pKa = 5.5) were deprotonated.
2.2. NMR spectroscopy
NMR spectra of losartan in the three various environments
were recorded on Varian 600 MHz spectrometers. 2D NMR experiments
as DQF-COSY, 1H–13C HSQC and 1H–13C HMBC conﬁrmed the resonances
assignment. A series of NOESY experiments in DMSO using mixing times
of 75 ms, 150 ms, 300 ms and 1 s revealed that the mixing time of
150 ms could ensure the operation at the initial linear part of the NOE
buildup curve. 2D NOESY and ROESY experiments were performed
using a mixing time of 150 ms in the phase-sensitive mode and the
WET sequence to suppress the water signal in the aqueous and micellar
solutions. ROESY spectra were acquired using 4 KHz spin-locking ﬁeld
strength. Interatomic proton–proton distances were calculated using the
two-spin approximation and the integrated cross peaks intensity of a
pair of adjacent aromatic protons assumed to have a distance of 2.46 Å.
The resulting distances were corrected for the frequency offset [39].
Upper and lower limit constraints were estimated as ±10% of the result-
ed value.
DOSY experiments were recorded at 298 K using the Bipolar Pulse
Pair Stimulated Echo (Dbppste) pulse sequence of Varian library with a
gradient duration of 2 ms, a diffusion delay of 50 ms and an array of 15
values for gradient strength varying between 1000 and 25,000 G cm−1.Spectrawere processed using the BayesianDOSY transform implemented
in Mnova s/w. The uncertainty of the translational diffusion constant D
has been evaluated to 10% based on the average error estimation of the
diffusion coefﬁcients of the distinct resonance peaks as performed in
VnmrJ analysis routines.
2.3. Molecular modeling
2.3.1. Molecular modeling in implicit solvent
MD simulations were performed using the Stochastic Dynamics
method of the Maestro (v.9.5) MacroModel module [40] and the
OPLS-2005 force ﬁeld. The simulation temperature was 300 K in order
to mimic the spectroscopic experimental conditions. Solvent effects
were simulated using the Generalized Born/Surface Area (GB/SA)
solvation model and setting the values of the dielectric constant
ε = 45, 80 and 32 for DMSO, water, and SDS micellar environments,
respectively. The choice of the dielectric constant for the micellar
environment was based on literature data determined from pyrene
ﬂuorescence spectroscopic measurements in SDS micelles in the
absence of NaCl [41]. The applied dielectric constant is also in a good
agreement with an estimate of the polarity of the interface between
lipid bilayers and bulk aqueous solution (ε ~ 35) [42].
The crystallographically-determined structures of losartan [8–10]
were used as initial ligand conformations. The MD runs included
a stage of 2 ns equilibration and 10 ns simulation. The integration
time-step was set to 1 fs. Unconstrained and constrained MD simula-
tionswere performed and in the case of the latter, NMRderived distance
restraintswere appliedwith a force constant of 3 kcal mol−1 Å−1 and a
(±10%) uncertainty. All critical dihedral angles were monitored during
the simulation.
A grid scan search was used to explore the energy landscape of the
drug by systematically varying the critical dihedrals τ2 and τ3 by 10°
using the Coordinate Scan algorithm of the MacroModel module [40].
2.3.2. Molecular modeling in SDS micelles
The initial coordinates of a pre-equilibrated micelle structure of 60
SDS molecules were kindly provided by Prof. Alexander MacKerell
[34]. The initial model system was fully minimized with Molecular
Mechanics (MM) using MacroModel 9.5 [40] and the OPLS-2005 force
ﬁeld, implicit water solvent (GB/SA continuum solvation treatment),
and extended non-bonded cutoff. The minimization was carried out
using the Polak–Ribiere Conjugate Gradient (PRCG) method with
convergence movement threshold of 0.001 kJ mol−1 Å−1.
Following the relaxation of the micelle structure, the losartan
anionic formwas placed randomly ~5 Å away from themicelle surface.
The merged system was solvated in an orthorhombic simulation buffer
box of size 20 Å in each direction with 17363 TIP4P water molecules
and 61 sodium counterions, randomly distributed in the aqueous phase.
MD simulations were performed with Desmond 3.1 [43] using
the OPLS 2005 force ﬁeld. Before the production run, the model
system was relaxed through a series of minimizations and short MD
simulations were performed using Desmond default values. Production
runs were performed in the NPT ensemble at 300 K and 1.01325 bar
with periodic boundary conditions for 20 ns. The RESPA integrator
[44] was used with time step 2 fs for bonded and short-range interac-
tions and 6 fs for long-range interactions. During equilibration the
Berendsen thermostat and barostat [45] were applied with coupling
time constants of 100 ps and 1000 ps, respectively. The cutoff distance
for the Coulombic interactions was set to 9 Å, while the long range
Coulombic interactions were calculated using the smooth Particle
Mesh Ewald (PME)method [46] with a tolerance of 1e-09. Visualization
of the trajectories was performed using Maestro (Schrödinger, LLC)
[47]. The calculation of the distance between the center of masses of
losartan and the micelle throughout the trajectories was performed
with the “center of mass” (COM) and “distance states” scripts of
PyMOL [48].
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embedded receptor
The topology and the coordinates of a pre-equilibrated 128 DPPC
lipid bilayer were downloaded from Peter Tieleman's Biocomputing
Group website [35]. The 128-DPPC lipid bilayer was replicated along
the xy plane to produce a membrane of 512 DPPC lipids. The resulting
system was subjected to 500 steps of Steepest Descent (SD) energy
minimization followed by an equilibration of 10 ns MD simulation
with the GROMACS 4.5.4 package and the GROMOS 53a6 force ﬁeld
[49,50]. The area per lipid of the bilayer reached a plateau after 4 ns
at 61 ± 0.4 Å2, which agrees very well with the experimental value
of 63 Å2 [51]. The bilayer structure from the last snapshot of this
simulation was extracted, placed in a 12.5 × 12.5 × 11 nm rectangular
box, and solvated. The new system was subjected to a 200 ps MD run
before inserting the modeled AT1 receptor [16]. The protein was then
embedded into the membrane employing the protocol implemented
in the GROMACS script g_membed [52]. Brieﬂy, the size of the protein
is scaled by a factor of 0.5 in the membrane plane. All lipid and solvent
molecules overlapping with the resized protein were removed and an
MD step is performed with all intra-protein interactions turned off.
Then, the resize factor is incremented by a small amount and the protein
is resized again followed by another MD step. This procedure is iterated
1000 times until the protein reaches its original size. In total, 28 DPPC
lipid molecules were removed yielding a lipid bilayer of 484 DPPC
lipid molecules evenly distributed in the two leaﬂets. Subsequently,
eight losartan molecules were added to the system. Special care was
taken so as to place losartan molecules in different positions in the
simulation box: four of them were placed in the water phase, two at
the lipid–water interface and two in the interior of the DPPC bilayer.
All losartan molecules were placed randomly at a distance at least
20 Å away from the receptor. The system was then neutralized by
adding a sufﬁcient number of Cl− counter ions. The size of the ﬁnal
AT1/DPPC/Water/8losartan/Cl− system was 136,781 atoms. After an
energy minimization using the Steepest Descent method, the system
was subjected to a 2 ns MD simulation applying harmonic positional
restraints (1000 kJ/mol/nm2) on all protein atoms to allow equilibration
of the protein–lipid interface, followed by a 5 ns MD simulation
run with the protein restraints removed. Finally, a 580 ns production
run was carried out. To ensure proper convergence of the system
properties, the ﬁrst 100 ns of the simulation were discarded as
equilibration.
All energyminimizations and MD simulations were performed with
GROMACS 4.5.4 software package using the GROMOS 53a6 force ﬁeld
updated with the Berger lipid parameters. The SPC water model was
used and standard GROMOS parameters for losartan were obtained
from the PRODRG server [53]. The bond parameters for the C\Cl bond
resulting from the PRODRG server were different from the standard
GROMOS parameters. Therefore, these were altered to the original
GROMOS C\Cl parameters (bond length: 0.176 nm, bond force
constant: 8,100,000 kJ/mol/nm2). All other parameters were left
unchanged. Harmonic restraints (600 kJ/mol/rad2) on the improper
dihedrals of losartan were placed to ensure ring planarity. Moreover,
due to the fact that partial atomic charges generated by PRODRG are
not compatible with GROMOS force ﬁelds [54], the losartan atomic
charges were determined from ﬁtting the quantummechanical electro-
static potential of themolecule using the package NWChem 6.0 [55,56].
In these calculations, the total charge imposed on losartanwas zero and
the sum of the atomic charges in the tetrazole, imidazole, methyl, and
two phenyl groups was constrained to zero following the GROMOS
force ﬁeld conventions for the deﬁnition of charge groups. All bonded
and non-bonded parameters of losartan were tested by running a 5 ns
MD simulation of the molecule in vacuo in which the conformational
ﬂexibility of its chemical groupswas visually examined.MD simulations
of the AT1/DPPC/Water/Losartan systemwere run in the NPT ensemble
at 323 K and 1 bar with periodic boundary conditions. The leap-frog
integrator was used to solve the equations of motion with a 2 fsintegration time step. The temperature of the system was controlled
with the Nose–Hoover thermostat and a coupling time constant of
0.5 ps. The Parrinello–Raman barostat with a coupling time constant
of 5 pswas used to control pressure. Electrostatic interactionswere cal-
culated with the PMEmethod using a 1.4 nm cutoff for the direct space
sum. For the van der Waals interactions, the Lennard–Jones potential
was smoothly switched off from 0.8 to 1.2 nm. All bonds were
constrained using the LINCS algorithm.
3. Results and discussion
3.1. NMR spectroscopy
Structural elucidation and conformational analysis of losartan
in DMSO have been already reported in a previous publication [7]. The
current study investigates further the conformational features of the
drug in the aqueous and SDS micellar environments. Two different
concentrations of the drug, namely 5 and 15 mM were examined
relatively to their NMR proﬁling in the different environments. Chemical
shift variations as well as differentiation of the B aromatic ring pattern
were observed between the different concentrations of the drug in
aqueous solution, while the DMSO and micellar environment proﬁlings
showed no concentration dependence.
1H NMR spectra of the drug in DMSO, D2O and SDS micelles are
shown in Fig. 2 and Table 1 displays 1H NMR chemical shifts of losartan
at the two concentrations used 5 mM and 15 mM in the three different
environments.
3.1.1. Comparison of the 1H NMR proﬁling of losartan in the
different environments
Inspection of the 5 mM 1H NMR spectral patterns of the drug in the
three different environments (i) DMSO, (ii) D2O, and (iv) SDS displayed
in Fig. 2 reveals that the higher polarity of D2O causes an upﬁeld shift,
relative to the amphiphilic DMSO and micellar solutions, of the alkyl
chain and A phenyl ring protons, ranging between 0.1 and 0.15 ppm.
However, this tendency is not observed for phenyl ring B with the
exception of H22 adjacent to the tetrazole anion.
The upﬁeld shift of the alkyl chain and the A ring protons in the
aqueous environment is probably associated with a conformational
redistribution, which may lead to an increase of gauche conformations
of the alkyl chain as well as to the involvement of CH–π interactions
[57,58]. Furthermore, the dipolar interactions betweenwatermolecules
and the tetrazole ring could induce the observed shielding of the
neighboring H22.
The hydrogen bond acceptor DMSO appears to induce hydrogen
bonding with the imidazole hydroxyl group, which is supported by
the presence of the –OH resonance peak shifted towards higher
frequency scale (at 5.2 ppm) and by the observed splitting pattern of
this peak (triplet, J = 5.3 Hz) in combinationwith the doublet coupling
pattern of methylene H6. This coupling, present only in the DMSO
environment, may result from the increased stability and slow
exchange rate of the hydroxyl proton.
Evidence for a concentration dependent self-assembly behavior of
losartan in aqueous environment is provided by (a) 1H NMR proﬁle
differentiation, (b) Transverse relaxation (T2) time measurements, and
(c) DOSY spectroscopy.
1H NMR proﬁle differentiation. Increase of the concentration in
aqueous solution from 5 mM to 15 mM (Fig. 2 ii and iii, respectively)
increases further the upﬁeld shift of the resonances and alters the B
ring 1Hproﬁle. The difference in pDbetween the two studied concentra-
tions of losartan cannot account for the observed signiﬁcant chemical
shift changes. Such a concentration dependence of the chemical shifts
in D2O has been reported in the literature for systems bearing
unprotonated nitrogen heterocycles, and has been attributed to aromat-
ic stacking behavior and subsequent aggregation [59].
Fig. 2. 1H NMR representative spectra of losartan (upper part: aromatic and lower part: aliphatic region). (i) 5 mM inDMSO-d6 (ii) 5 mM in D2O (iii) 15 mM in D2O (iv) 5 mM in SDS-d25
micelles solution. Additional peaks in the alkyl region of losartan in micelles (denoted with *) are due to residual protons of SDS-d25.
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decrease of the B aromatic ring mobility associated with the increased
concentration in D2O solution. This decrease in mobility is particularly
prominent for proton H19 (93% decrease) (Supplementary Material,
Fig. S1) and presents an additional indication for the formation of
assemblies as the concentration increases. The presence of K+ ions in
the solution could possibly induce the formation of assemblies with
the ionized losartan tetrazole moieties. Such interactions impose
limitations to the mobility of the tetrazole ring and further to the
adjacent phenyl ring. Coordination patterns have been reported for
the crystal structures of losartan potassium [8,9].
DOSY spectroscopy has been established as a new method to detect
the presence of assemblies. Interpretation of DOSY data for the two
drug concentrations in aqueous solution (Fig. 3a and b) revealed a
higher diffusion constant associated with the 5 mM concentration(D = 2.6 ± 0.3 × 10−10 m2 s−1). The more concentrated solution
(15 mM) displayed a double series of traces with lower constants
(D = 2.3 ± 0.2 × 10−10 m2 s−1 and D = 2.0 ±0.2 × 10−10 m2 s−1)
in a ratio of 4.6:1, implying the formation of assemblies comprised
of different number of losartan molecules, resonating in an average
chemical shift. The obtained experimental data corroborate with the
assumption of concentration dependent self-assembly behavior of
losartan in aqueous environment possibly associated with the anionic
tetrazole and the presence of K+ counterions in the solution. Interesting-
ly, no concentration dependence of the chemical shifts, neither of the
transverse relaxation times, nor of the self-diffusion coefﬁcient was
observed for the aqueous solution of the AT1 antagonist valsartan,
which bears a protonated tetrazole ring [32]. Furthermore, the potent
metabolite of losartan, EXP-3174, which was studied in its neutral form
in DMSO and in aqueous solutions, exhibited a similarly well resolved B
Table 1
1H NMR chemical shifts of losartan in DMSO-d6, D2O and micelles. Two different concen-
trations were studied, 5 mM and 15 mM. Chemical shift variations were only observed in
aqueous environment.
Atoms Losartan in different environments
DMSO
5 mM/15 mM
D2O Micelles
5 mM/15 mM
5 mM 15 mM
H10 0.78 t 0.62 t 0.58 0.77
H9 1.23-sextet 1.6-sextet 1.0 1.22
H8 1.45-quintet 1.31 1.26 1.5
H7 2.47 t 2.4 2.32 2.52
H6 4.29d 4.32 s 4.24 4.39
H11 5.80 s 5.08 s 5.0 5.15
OH 5.2 t – – –
H-13/17 6.87d 6.73d 6.63d 6.85d
H-14/16 7.06d 6.89d 6.79 6.99
H19 7.24dd 7.32d 7.17dd 7.27d
H20 7.32 m 7.45 m 7.6 m 7.34 t
H21 7.32 m 7.9 t 7.36 m 7.41 t
H22 7.51dd 7.45 m 7.44dd 7.64d
Reference DMSO: 2.49 D2O: 4.7
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corresponding spectra obtained at the increased concentration are pre-
sented in Fig. S2 of the Supplementary material.
3.1.2. Association of losartan with micelles
In order to exclude any self-assembly effects, a drug concentration of
5 mMwas chosen for the study of losartan interactionwithmicelles. An
excess concentration of 400 mM was used for the micelle aiming to
ensure the immersion of at least one drug molecule in the detergent
aggregates. The increase of the 1H NMR linewidth compared to theFig. 3. DOSY spectra of (a) 5 mM Los in D2O (b) 15 mM Los in D2Owater solution, indicated the interaction of the drug with micelles
(Fig. 2, iv). Diffusion experiments also conﬁrmed the association of the
drug molecules with the micellar aggregate. More speciﬁcally, the inser-
tion of the drug in the micellar environment was accompanied by a re-
duction of the diffusion coefﬁcient (D = 4.3 ± 0.4 × 10−11 m2 s−1)
(Fig. 3d), which is one order of magnitude less than the aqueous or
DMSO environment (D = 1.6 ± 0.2 × 10−10 m2 s−1) (Fig. 3c).
Inspection of a single set of 1H resonance lines as well as the observation
of a single series of DOSY traces corroborate with a fast chemical
exchange between the free and the micelle-bound states of the drug.
Thus, the calculated diffusion coefﬁcient reﬂects the average value of
the two exchanging entities.
The mobility of losartan in the micellar environment was also
investigated through transverse relaxation measurements. The notable
decrease of spin–spin relaxation time compared to the aqueous solution
is indicative of the afﬁnity of losartan to SDSmicelles. In addition, the sim-
ilarity in T2 values as measured for all resonance peaks indicates that all
moieties of themolecule interactwith themicelle (SupplementaryMate-
rial, Fig. S1). In the amphiphilic DMSO environment, the transverse relax-
ation times are comparable to those in themicellar environmentwith the
exception of the terminal methyl H10 and the spacer methylene H11,
which retain their ﬂexibility (Supplementary Material, Fig. S1).
3.1.2.1. Use of spin labels to locate losartan in the micellar environment. To
determine the drug topography in themicellar aggregate, solution NMR
relaxation probes were used. The 5-doxylstearate (5-DSA) spin label
bears a nitroxide near the head of the stearate and induces relaxation
of the NMR signals of the drug moieties in the proximity of the micelle
surface, while 16-doxylstearate (16-DSA) spin label has a nitroxide
near the end of the alkyl chain of the stearate and affects the resonances
of losartan protons located deep in the hydrophobic region of the(c) 5 mM Los in DMSO-d6 (d) 5 mM Los in 400 mM SDS-d25.
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micellar solutions in an effort to keep a satisfactory S/N for a reasonable
observation of the distinct resonances.
Resonance peaks were deconvoluted and the calculated half widths
were used to report the paramagnetic broadening upon the successive
additions of 5-DSA and 16-DSA. The chart in Fig. 4 displays the variation
of the half linewidth for characteristic resonance peaks representing the
different functionalities of the drug as the alkyl chain (methylenesH7 and
methyl H10), themethanol protons H6, the spacer methylene H11, the A
aromatic ring (H13/17), and the B aromatic ring (H19, H20 and H22).
The incorporation of 5-DSA free radical showed a notable increase of
half-width of the alkyl chain peaks as well as of the B ring protons H19,
H20 and a less pronounced broadening of the A ring protons, of the
methylenes H11 and H6, and the B ring proton H22.
The paramagnetic effect of 16-DSA located deep in the hydrophobic
segment of micelles is clearly reduced compared with 5-DSA. In this
case, alkyl chain protons and speciﬁcally the ﬁnal methyl and the B
ring protons H19 and H20 are more susceptible to the presence of the
nitroxide spin label. To a lesser degree the resonances of the A ring
H13/17 and methylene H11 are also inﬂuenced. Notably, the effect
upon the resonance lines of H6 and H22 is practically negligible.
The obtained results support a location of losartan near the micellar
surface since the interaction with 5-DSA is notably more prominent
than the one with 16-DSA. Furthermore, evidence of the preferred
orientation of losartan's pharmacophores is also provided. Speciﬁcally,
the hydroxymethyl group and B ring proton H22 adjacent to the
tetrazole face the micelle–water interface, whereas the butyl chain and
the B ring protons H19 and H20 are interacting with the hydrophobic
center of themicelle. These experimental data do not indicate preference
for the anti or syn conformation in the detergent environment; however
an arrangement of the butyl chain towards themicellar core is conﬁrmed.
3.1.2.2. Probing drug:micelles intermolecular interactions. In an effort to
elucidate further the drug:micellar aggregates interaction sites, ROESY
cross relaxation experiments have been carried out. A drug concentration
of 15 mM in D2O solutions of 200 mM SDS-H25 or 200 mM SDS-d25
(drug:micelle preparations B) was used. Fig. 5 displays overlaid
corresponding regions from the experiments with the protonated and
the perdeuterated detergent, enabling the discrimination between the
intra- and inter-molecular interactions of losartan. SDS resonance
lines have been assigned according to the reference [59].
Strong intermolecular ROEs are observed between the two aromatic
rings, the spacer methylene H11, the hydroxymethyl H6 as well as the
alkyl chain methylene H7 and SDS protons S3–11, which are attached
to the third carbon after the sulfate group till the penultimate one. The
evaluation of the ROEs intensities can only be qualitative due to the
extensive spin diffusion along the detergent alkyl chain. Moreover,-0.50
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Fig. 4. Broadening of half linewidth of losartan resonance peaks (relative half linewidth change)
as rad16 in the micellar solution in a molar ratio of 1:4 (spin label:drug). * The absence of th
distortion of the lineshape.severe overlap with the SDS resonance lines obscured possible ROE sig-
nals with the rest of the butyl chain of losartan. The obtained results
though indicate clearly that losartan is distributed in the vicinity of the
hydrocarbon chains.
Furthermore, the protons of the A ring (H13/17 and H14/16) as well
as themethylene H7 appear to be in contact with SDS proton S2 attached
to the second carbon after the sulfate group, providing evidence that
losartan is also interacting with the head groups of the micelle. Although
the terminal SDS methyl S12 overlaps with losartan butyl chain methyl
H10 preventing deﬁnite conclusions, a lack of observed NOEs between
the B aromatic ring and hydroxymethyl protons H6 with S12 further
supports their orientation towards the polar headgroup of the micelles.
Valsartan was also observed to interact strongly with the aliphatic
chain of SDS S3–11. However, the lack of intermolecular NOEs with the
S2 position of the detergent most probably indicates a deeper insertion
of valsartan relatively to losartan [32].
3.1.3. NOE connectivities and conformational analysis of the drug in the
different environments
In an effort to elucidate the conformational differences of the mole-
cule in the three different studied environments, quantiﬁcation of the
interatomic distances was deemed necessary. Thus, NMR spectroscopic
studies using the ROESY/NOESY methods have been repeated for
losartan in DMSO and extended to aqueous and micellar environments.
A drug concentration of 5 mMwas used in all cases and themicelle was
formed by 400 mM SDS-d25 in D2O solution (drug:micelle preparation
A). Integration of ROE and NOE cross peak signals gave similar results.
The corresponding ROESY spectra are provided at the Supplementary
Material (Supplementary Material, Fig. S3–S5) and the calculated
interatomic distances are shown in Table 2.
The striking difference between the three studied environments is
reﬂected in the ﬂexibility of the butyl chain. The plethora of ROEs
observed in DMSO or micelles between the chain protons and the A
ring (i.e. H7, H8, H9with H13/17) as well as between the chain protons
and the spacer methylene (H8, H9 with protons H11) suggest a pre-
dominant arrangement of the chain in a close proximitywith the A ring.
The greaterﬂexibility of the alkyl chain in the aqueous environment is
reﬂected by the absence of characteristic ROEs (i.e. between H9 and H11
or betweenH9 and A ring protons). The enhanced conformationalmobil-
ity of the chain in the aqueous environment has also been observed by
crystallographic studies of losartan potassium. It was suggested that
while biphenyltetrazole moieties form coordination interactions mediat-
ed byK+ cations, the atomsof the chain and the imidazole ring except the
oxygen atom, which also participates in the coordination sphere of the
metal ion, are highly agitated and disordered [9].
In agreement with the relaxation time measurements, the confor-
mational ﬂexibility of the drug in DMSO and micellar environments13 19 20 22
bering
5 uL rad5
10 ul rad5
15 ul rad5
20 ul rad5
5 ul rad16
10 ul rad16
15 ul rad16
20 ul rad16
upon successive additions of 5-DSA denoted as rad5 (dot bar graphs) and 16DSA denoted
e broadening bar for methyl protons H10 at the 4th addition of 16-DSA is due to serious
Fig. 5.ROE interactions between the drug and themicelle. Overlaid are expanded regions from the spectra of 15 mM losartan in 200 mMSDS-H25 (gray traces) and in SDS-d25 (red traces).
The mixing time used was 150 ms. The depicted horizontal and vertical 1D traces correspond to the protonated detergent solution.
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alkyl chain in the micelles with respect to bulk water indicates that
the drug:membrane interactions and the diffusion mechanism through
the biological membrane, mimicked in the current study by micelle
aggregates, contributes to the reduction of the entropy of losartan
while it diffuses through the membrane to the receptor site.
3.2. MD simulations
3.2.1. MD simulations of losartan in implicit solvation environments
The experimentally derived interatomic distances could not
determine unambiguously whether the anti or syn conﬁguration of theTable 2
Interatomic proton–proton distances (Ǻ) derived from ROESY spectra for losartan in different
throughout the course of MD simulations in micelles and in DPPC lipid bilayer with the AT1 re
at 5 Å in order to correspond to the experimentally-measured values.
Losartan atoms Experimental interatomic distances
(calculated from ROE data
with a st. dev. of ±10%)
5 mM losartan in
DMSO D2O 400 mM SDS-d25 Anti initia
10 7 3.4 3.7 3.4 3.9
10 8 3.1 3.4 2.6 2.6
9 7 2.8 3 2.6 2.6
9 11 3.6 – 3.7 4.5
9 13/17 3.7 – 3.6 4.8
8 11 3 3 3 3.9
8 13/17 3.4 3.5 3.5 4.2
7 11 2.2 2.3 2.2 2.3
7 13/17 3.1 3 3 3.5
6 11 2.5 2.3 2.6 3.5
6 13/17 2.8 2.9 3 3.4
11 13/17 2.4 2.6 2.6 2.8
19 14/16 2.5 2.6 2.7 3.5drug is the predominant one in solution. Thus, in a further step, we in-
vestigated the dynamic stability of the various energetically favorable
conformers by applying MD simulations using implicit solvation meth-
od for the three studied environments (DMSO, D2O, SDS micelles).
Different initial conformations of the drug, including all crystallo-
graphically determined structures [8–10], were subjected to uncon-
strained and constrained MD simulations using the NMR derived
interatomic distances as restraints.
Analysis of the trajectories in all studied implicit solvation envi-
ronments supports the following conclusions: (a) Unconstrained
MD simulations reveal the prevalence of the syn conﬁguration
throughout the simulation time; (b) Restraining the ﬂexibility ofsolvents and in micelles. Comparison with the average values of the distances measured
ceptor embedded. The values calculated from the DPPC:losartan:AT1 system were cut off
Average values calculated during the course of
MD simulations
Micelles Lipid bilayers
l conformer Syn initial conformer Average of the 8 losartan molecules
3.9 3.6 (0.3)
2.6 2.5 (0.1)
2.6 2.5 (0.1)
5.0 5.1 (0.4)
4.5 4.5 (0.3)
4 4.1 (0.3)
4.5 4.4 (0.4)
2.3 3.1 (0.1)
3.5 4.0 (0.4)/4.1 (0.4)
3 3.1 (0.1)
3.6 4.1 (0.4)/4.0 (0.6)
2.4 2.4 (0.04)
3.5 3.2 (0.1)
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and between H6–H13/17 is the prerequisite for the dynamic stability
of the anti conformation issuing a smooth potential energy curve
along the MD simulation although the energy is ~7 kcal mol−1 higher
with respect to the unconstrained MD; (c) The conversion of the anti
to syn conformationwasnot hindered by imposing a distance constraint
between H14/16–H19, thus restraining τ2 dihedral.
The last two observations indicated that the interconversion
should rely solely on the rotation around the critical torsion angle
τ3. To investigate further the energetic cost of this transition, a
grid scan search was performed by systematically varying the dihe-
drals τ2 and τ3. As observed from the heat map of Fig. 6 the energy
minima are located symmetrically at τ2 = 60° and 120° indicating the
unobstructed ﬂuctuation of the phenyl-tetrazole moiety around the ver-
tical position with respect to the neighboring A phenyl ring. As a general
rule, the anti conformers bear the torsions τ2 and τ3 with the same sign,
while the syn conformers adopt opposite sign for those angles. As already
shown in our previous publication [7], the transition from the anti to syn
by rotation around τ2 (i.e. moving from conformer A towards conformer
C following a trajectory parallel to dihedral τ2 axis) is extremely
energy demanding since a barrier of 8 kcal mol−1 needs to be over-
come. On the other hand, the energy proﬁles of Fig. 6 reveal that the
interconversion between the syn and anti conformations is notably
more energetically favorable by rotation around τ3 since the energy
barrier to be overcome is ~2 kcal mol−1 (i.e. transition from conformer
B to conformer C moving parallel to the dihedral τ3 axis). Moreover,
unhindered rotation around τ3 inﬂuences the positioning of the butyl
chain drifting it above the A ring plane (i.e. conformations B and C in
Fig. 6) or below the plane (i.e. conformations A and D in Fig. 6) in the
same or opposite side of the space occupied by tetrazole, respectively.3.2.2. MD simulations of losartan-loaded SDS
MD simulations were run with the losartan anionic form (both
syn and anti orientations of the tetrazole with respect to the imid-
azole) placed randomly ~5 Å away from the surface of SDS aggre-
gates in the aqueous environment. The drug was placed in the
aqueous environment in order to study i) its spontaneous insertion
into the micelle and further diffusion into the micelle core and ii)Fig. 6.Heatmap illustrating the energy landscape (in kcal mol−1) resulting from the grid scan s
rule, the anti conformers bear the torsions τ2 and τ3 with the same sign, while the syn conformpotential conformational changes induced by its interaction with
the micelle.
MD simulations show that both conformers (syn and anti)
approach the micelle surface very quickly (in the ﬁrst 2 ns of the
simulation time) and diffuse between the polar headgroups and
the upper part of the alkyl chains of SDS (Fig. 7). This localization
favors the formation of hydrogen bond interactions between the
hydroxyl group of losartan and the sulfate group of SDS as was
observed in approx. 20% of the trajectories frames collected from
the MD simulations.
In Fig. 8, the approach of the drug into themicellar interface is graph-
ically represented by the plot of the distance between the center of
masses of losartan and of micelle versus the simulation time.
Interestingly, the conformational behavior of syn and anti orien-
tations of the drug throughout the MD simulations is different. The
anti conformer is preserved during most of the simulation time as
depicted in Fig. 9A. On the other hand, the syn conformer is exchang-
ing between the 2 states during the ﬁrst 13 ns and then it is stabi-
lized to the anti one for the rest of the simulation time (Fig. 9B). Thus,
the molecular dynamics approach points to the anti conformation as
being most favorable in the micellar environment. Regarding the unhin-
dered ﬂunctuation of τ2 around 90° as observed in the conformational
analysis, this is also evident in themicellar environment (Supplementary
material, Fig. S6). Themean values of the interatomic distances during the
simulation time for both initial conformations of losartan (Table 2) were
found to be very similar with the NMR derived values.3.2.3. Interactions of losartan with AT1 receptor embedded in a
bilayer environment
MD simulations of losartan in a DPPC lipid bilayer with the AT1
receptor embedded were also performed in order to study: a) the
conformational dynamics of losartan in a lipid bilayer and at the
vicinal region of AT1 receptor; b) the positioning of losartan in
the bilayer; and c) the diffusion pathway of losartan in the
bilayer.
Losartan molecules were initially placed randomly in the water and
lipid bilayer phases at a minimum distance of 20 Å from the AT1 recep-
tor. It is evident from the simulations that losartan shows a strongearch by varying the dihedrals τ2 and τ3. Low energy conformers are depicted. As a general
ers adopt opposite sign for those angles.
Fig. 7. Three snapshots of losartan (anti conformer, top) and (syn conformer, bottom)with the SDSmicelleMD trajectory. At the beginning of the simulation time (0 ns) the drug lies in the
aqueous environment outsideof themicelle, after 2 ns it has approached themicelle surface, and then it is immersedwithin themicelle and practically localizes between the sulfate groups
and the upper part of the dodecyl chains.
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phase,which is not surprising given the signiﬁcant hydrophobic compo-
nent of the drug solvent-accessible surface area [31]. Within the ﬁrst
few ns all losartanmolecules partition spontaneously in the DPPC bilay-
er from the water phase with the exception of one molecule, whichFig. 8. Plot of the distance between the center of masses of losartan (antinteracts with the extracellular part of the AT1 receptor. Likewise, all
losartan molecules initially placed within the lipid bilayer remain
there for the rest of the simulation time (Fig. 10). Losartan molecules
diffuse freely along the membrane plane remaining close to lipid head
groups and the water:bilayer interface (see Supporting video).i in blue, syn in red) and of micelle throughout the simulation time.
Fig. 9.Heat maps depicting the distribution of losartan torsion angles τ2 and τ3 throughout the simulation time in SDSmicelles for the anti (A) and the syn (B) initial conformers. The anti
conformation is characterized by values of τ2 and τ3 bearing the same sign while the syn conformation by values of τ2 and τ3 of opposite signs.
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cases, losartan positioned itself with the imidazole ring pointing toward
the bilayer interface and the hydrophobic side chain embedded in the
bilayer. Hydrogen bond analysis conﬁrmed that losartan molecules
interact predominantlywith the lipid glycerol backbone and headgroup
forming, on average, 0.35 hydrogen bonds per molecule with the
carbonyl and ether oxygen atoms (total for all losartan molecules:
2.5 ± 1.4) and 0.35 hydrogen bonds per molecule with the phosphate
group of the DPPC headgroup (total for all losartan molecules:
2.4 ± 1.4) (Supplementary material, Fig. S7a and d, respectively). The
main contribution to hydrogen bonding of all losartan molecules with
the DPPC glycerol backbone arises from the tetrazole moieties
(1.8 ± 1.1), while the hydrogen bonds of the losartan hydroxymethyl
groups to the glycerol backbone are limited to 0.6 ± 0.7 (Supplementa-
rymaterial, Fig. S7b and c, respectively). These hydrogen bond contribu-
tions are reversed for the interactions of losartan with the DPPC
headgroup. In this case, the main contribution to hydrogen bonding of
losartan with the phosphate group of DPPC arises from the losartan
hydroxymethyl groups (2.4 ± 1.4 hydrogen bonds in total) relatively
to the minor contribution of the tetrazole moieties, which form only
0.6 ± 0.7 hydrogen bonds (Supplementary material, Fig. S7f and e,
respectively). The imidazole group did not form any hydrogen bonds
with the DPPC headgroup throughout the course of the simulation.
These data indicate a positioning of losartan consistent with the
hydroxymethyl group pointing toward the DPPC headgroup, while the
tetrazole moiety is oriented toward the DPPC glycerol backbone. Inter-
estingly, despite the fact that all but one losartan molecules remain in
the membrane throughout the simulation, they do form hydrogen
bonds with water molecules that are close to or have penetrated the
lipid bilayer yielding an average number of 1.6 hydrogen bonds for
eachmolecule (total for all losartanmolecules 11.6 ± 3.4). The tetrazole
and hydroxymethyl moieties form on average one hydrogen bond with
water in each molecule (Supplementary material, Fig. S7g–i). The imid-
azole moiety is buried under the hydroxymethyl group and positioned
around the area of the glycerol backbonewithout forming any hydrogen
bondswith the DPPC headgroup. However, it exhibits occasionally polar
interactions with water at an average of 0.2 hydrogen bonds per mole-
cule (Supplementary material, Fig. S7j). It should be also noted that
losartan engages into infrequent intramolecular hydrogen bonding be-
tween its hydroxyl and tetrazole groups.
3.2.3.1.1. Intermolecular interactions — Solvation of losartan by DPPC
molecules in the bilayer. To further investigate the intermolecular inter-
actions of losartan with the lipid bilayer, radial pair distributionfunctions, g(r), for several types of interactions were calculated. The
g(r) were estimated here from the equation
g rð Þ ¼ V
N
n rð Þ
4πr2dr
 
where V is the volume of the simulation box containing N particles, and
n(r) is the number of particles y in the sphere of radius r and width dr
around particle x. The ﬁrst and second solvation shell occupancies
may be calculated from the respective g(r) functions by integrating up
to the ﬁrst and second minima, respectively (Table 3).
The solvation of the losartan hydroxyl by the DPPC glycerol
backbone and headgroups, as calculated by the radial pair distribution
function, is shown in Fig. 11a,b. A small sharp peak at 2 Å and a larger
pronounced peak at 4 Å indicate that losartan hydroxyls are strongly
solvated by the DPPC glycerol backbone and headgroup area and have
on average two DPPC glycerol backbones and two DPPC headgroup
neighbors at 4 Å (Table 3). The losartan tetrazole also shows a small
sharp peak at 2 Å followed by another pronounced peak at 4 Å in the
radial distribution function with the glycerol backbone (Fig. 11c).
Integration up to the second minima shows that it has on average two
glycerol backbone neighbors (Table 3). The losartan tetrazole interacts
more strongly with the DPPC glycerol backbone rather than the DPPC
headgroup as it has one DPPC headgroup neighbor at 5 Å (Fig. 11d
and Table 3). Finally, the losartan butyl chain radial pair distribution
function (Fig. 11e) shows that the ﬁrst solvation shell of the butyl
chain from the DPPC headgroup is found at ~12 Å, which is consistent
with the observation that the butyl chain is buried in the bilayer
hydrophobic core. These results conﬁrm that losartan displays a strong
preference to reside in the interface and interior of the lipid bilayer. This
behavior may favor the assumption that losartan approaches the AT1
receptor through an intermediate partitioning with the membrane
rather than in a direct fashion.
3.2.3.2. Conformational dynamics of losartan. Losartan adopts a vertical
orientation for the tetrazole ring with respect to the adjacent aromatic
ring as seen from the distribution of dihedral angle τ2 (Supplementary
material, Fig. S8a) which shows a peak exactly at 90° as was also
found in the SDS micelle simulation. No other peaks are observed for
τ2 indicating that the molecule “locks” itself in this position with a
barrier of 8 kcal/mol (Supplementary material, Fig. S8b), in agreement
with the results of the conformational analysis of losartan and our
previously published studies [7].We observe that losartan interconverts
Fig. 10. Three snapshots of losartan in a DPPC lipid bilayerwith the AT1 receptor embeddedMD trajectory. Losartanmolecules were initially placed randomly in thewater and lipid bilayer
phases (t = 0 ns). Within the ﬁrst 10 ns all but one losartan molecules partition spontaneously in the DPPC bilayer from the water phase. One molecule interacts with the extracellular
part of the AT1 receptor. During the rest of the simulation time, losartan molecules diffuse freely along the membrane plane remaining close to lipid headgroups.
Table 3
First and second average solvation shells for various groups in the simulation.
g(r)a DPPC-losartan
First shell Second shell
Losartan hydroxyl – DPPC glycerol backbone 0 2
Losartan hydroxyl – DPPC headgroup 0.1 2
Losartan tetrazole – DPPC glycerol backbone 0.1 2
Losartan tetrazole – DPPC headgroup 0 1
a The ﬁrst solvation shell was calculated by integrating the corresponding pair radial
distribution function up to the ﬁrst minimum.
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(τ3 varying around−100°) conformations (Supplementary material,
Fig. S8c) with a barrier of ~2 kcal/mol (Supplementary material,
Fig. S8d) as also estimated from the systematic scan around the
dihedrals τ2 and τ3 (Fig. 6). This dynamic behavior is also mapped in
Fig. S9 of the Supplementary material, where a marginal predominance
of the anti conformation is observed after 400 ns of the simulation time
(half of the molecules prefer the anti conformation at an average
percentage of 67%), while it seems to prevail after 500 ns since 6 out of
8molecules adopt the anti conformation at an average percentage of 76%.
Fig. 11. Radial pair distribution functions of losartan (a) hydroxyl relative to DPPC glycerol backbone, (b) hydroxyl relative to DPPC headgroup, (c) tetrazole relative to DPPC glycerol
backbone, (d) tetrazole relative to DPPC headgroup, and (e) butyl chain relative to DPPC headgroup. Results are averaged over all losartan molecules, which are embedded in the bilayer.
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derived from theNMRdata,were also calculated from theMD trajectories
of the simulations in themembrane environment. The results are in good
agreement with the NMR measured values indicating the validity of our
approach (Table 2).
3.2.3.4. Diffusion of losartan in the bilayer. The diffusion of losartan within
the lipid bilayer embedding the AT1 receptor was calculated from the
linear regime (100–400 ns) of themean square displacement of themol-
ecules (Supplementarymaterial, Fig. S10). The lateral diffusion coefﬁcient
is D = 3.02 ± 1 × 10−11 m2 s−1, which is in excellent agreement with
the experimentally derived diffusion constant from DOSY NMR experi-
ments in the micellar environment (D = 4.3 ± 0.4 × 10−11 m2 s−1),
indicating that micelle aggregates can simulate in a very efﬁcient way
the membrane environment.
3.2.3.5. Diffusion of losartan toward the AT1 receptor. Only one losartan
molecule was found to encounter the receptor from the water phase
by interacting with the extracellular loops throughout the ~600 ns of
theMD trajectory. The rest are found to diffuse freely within the bilayer
though without approaching the receptor. Various reasons may beformulated justifying the inability of the drug to reach the active site
in this time scale either from the extracellular surface or through the
bilayer core.
(i) Obstacles reaching the active site through direct action on the
receptor. The homology model of AT1 used in the present study
was constructed using the bovine rhodopsin structure as a
template, where the extracellular loop 2 sits above the binding
site and encloses it. As already mentioned in the introduction, a
recently published model of AT1 based on the chemokine
CXCR4 receptor [21,22], is characterized by an open ECL2 loop,
presumably enabling easier doping of losartan; this issue will
be further investigated in future studies using the newer
homology model available. Therefore, the rearrangements
needed for our model to adopt the open state of the extracellular
loop 2 may occur in the ms time scale, whereas the time scale
reachable by the current state-of-the-art all-atom MD simula-
tions is in the order of μs. Moreover, different experimental MD
conditions may have to be used (i.e. higher temperature) in
order to increase the ﬂexibility of the ligand and receptor and
thus avoid the trapping.
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complexity of the membrane in a realistic system (containing
cholesterol, rigid ion channels, etc.) hinders the diffusion of the
AT1 receptor compared to our model, where the receptor may
freely diffuse in the plane of a pure DPPC bilayer. This higher
mobility of the AT1 receptor may not favor the encounter with
the drug molecules. Lastly, the diffusion of losartan toward the
active site of the AT1 receptor may be retarded by its stronger
binding to the headgroup and upper lipophilic segment of the
lipid bilayers.
In conclusion, the presented results were based on a simpliﬁed
membrane bilayer:receptor model of the much more complicated sys-
tem of natural membranes. Other factors inﬂuencing the partitioning
of the drug in themembrane could involve the induction of the interdig-
itation effect by the drug, the presence of cholesterol, which has been
shown to compete with drug incorporation in the membrane, or the
presence of domainswith high percentage of not well-packed phospho-
lipids such as dioleoylphosphatidylcholine, which facilitate drug diffu-
sion [60].
4. Conclusions
This study investigates the conformational features of losartan in
different environments simulating biological ﬂuids and membrane
bilayers. Moreover, in an effort to investigate the hypothesis of
spontaneous insertion and partitioning of losartan in the membrane
bilayer followed by lateral diffusion towards the AT1 TM receptor
we have applied an integrated methodology consisting of NMR experi-
ments and MD simulations approaches.
The drug can adopt twomajor conformations in solution positioning
the tetrazole and imidazole moieties in an anti or a syn orientation with
respect to the A phenyl ring plane. MD simulations in implicit solvation
models driven by NOE interatomic distances support the interconver-
sion between the anti and syn conformations, which are allowed by
the energetically favorable rotation around the critical torsion angle
τ3, which bridges the biphenyl tetrazole with imidazole.
Evidence for self-assembly behavior was observed in aqueous
solution at the highest studied concentration,which is possibly associated
with the charged tetrazole moiety of the drug and the presence of K+
counterions. Self-association of losartan at high concentrations in DPPC
bilayers has also been reported, resulting in the formation of drug-rich
and drug-poor domains and possibly retarding its diffusion towards the
AT1 receptor [14,31].
The drug topography in lipid environment was studied by NMR
relaxation probes and drug:micelle intermolecular ROE interactions,
which located losartan near the micellar surface. The hydroxymethyl
moiety and the tetrazole face the micelle–water interface, while the
butyl chain is positioned towards the micellar core. This topography is
also supported by MD simulations of losartan loaded in SDS as well as
in the membrane mimicking DPPC bilayer environment.
The spontaneous insertion of losartan in the lipidic core was
conﬁrmed by MD simulations in both micellar and lipid bilayers with
the AT1 receptor embedded. The drug approaches the lipid surface
from the aqueous environment within the ﬁrst few ns, swifts into the
bilayer and diffuses between the polar headgroups and the upper part
of the alkyl chains of the lipids. In accordance with the proposed
localisation of losartan, the long exploratory MD simulation run in the
DPPC lipid bilayer revealed the formation of hydrogen bonds with the
lipid glycerol backbone and the phosphate groups as well as isolated
water molecules penetrating the lipid bilayer. As a general trend, the
anti conformation of losartan seems to be the most favorable in both
the SDS and DPPC environments pointing to this conformer as the
bioactive one in a membrane environment.
The calculated interatomic distances in both membrane-mimicking
environments were in excellent agreement with the experimentaldistances measured by NMR. It is also noteworthy, that the calculated
lateral diffusion coefﬁcient in the lipid bilayer is perfectly in line with
the measured one from DOSY NMR spectroscopy in the micellar envi-
ronment. Our integrated approach is thus validated by the convergence
of the experimental and the theoretical data.
Overall, in silico and NMR approaches support the assumption that
the membrane environment serves as a pool of drug molecules locally
trapped and potentially diffusing towards the embedded AT1 receptor
active site. This localisation restricts the drug ﬂexibility and probably
contributes to the effective interaction with the receptor while it could
additional probe alternative pathways of entrance towards the AT1
active site beyond the random encounter at the extracellular part.
Furthermore, it has been reported that the free drugmolecules with
high membrane afﬁnity could be “trapped” inside the membrane
bilayer and consecutively bind to the same target and/or targets nearby,
even when their concentration in the bulk aqueous phase has already
dropped to insigniﬁcant levels [61]. In this respect, monitoring drug
interaction with membranes can provide valuable information for
designing new long acting drugs.
The aqueous-membrane “walk” of losartan at atomic resolution was
implemented as a continuation to our previous studies [11,31,62,63] on
the interactions of the amphiphiles AT1 antagonists with membranes
and the possible implication of the latter in the effective interaction of
the drugwith its target.Moreover, there is increasing evidence referring
to the beneﬁcial anti-inﬂammatory and neuroprotective efﬁcacy
of sartans either directly by blockade of the brain AT1 receptors or
indirectly by inhibiting further inﬂammatory cascades or maintaining
the functionality of the blood–brain barrier (BBB) during inﬂammation.
A number of studies have evaluated their effects with systemic admin-
istration thus probing to their ability to cross the BBB [64]. Their distinct
pharmacological proﬁle could also be related with the different degree
of sartans' permeability of the BBB. The effort to understand their
interactions with membranes might prove to be useful for gaining
insights of the sartan transportation mechanism in the human tissues,
and also for designing novel drugs with improved therapeutic proﬁle.
Supplementary data and supporting video to this article can be
found online at http://dx.doi.org/10.1016/j.bbamem.2013.12.012.Acknowledgement
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